Rates of Invasive Pneumococcal Disease in Adults With HIV in the Era of 13-Valent Pneumococcal Conjugate Vaccine, 2008-2018

September 29 - October 3, 2021; Virtual
Active surveillance demonstrates that introduction of PCV13 led to declines in IPD in people with and without HIV and suggests benefits of newly approved higher valency PCVs.
Format: Microsoft PowerPoint (.ppt)
File Size: 419 KB
Released: October 7, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Download slides reviewing the latest data and guidance on COVID-19 prevention and treatment in special populations, from Clinical Care Options (CCO)

Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Kristen Marks, MD Renslow Sherer, MD Released: May 18, 2022

Download slides reviewing the latest data and guidance on COVID-19 symptoms and clinical manifestations, from Clinical Care Options (CCO)

Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Kristen Marks, MD Renslow Sherer, MD Released: May 17, 2022

Preguntas respondidas por expertas de Clinical Care Options (CCO) sobre las mejores prácticas para cambiar el TAR en pacientes suprimidos en México.

person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Released: May 17, 2022

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN Jasjit Gill, BSPharm, PharmD
Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 10, 2022 Expired: May 9, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings